Table 8

Refinements of the IPSS-R beyond the IPSS

1. New marrow blast categories
    ≤ 2%, > 2%-< 5%, 5%-10%, > 10%-30%
2. Refined cytogenetic abnormalities and risk groups
    16 (vs 6) specific abnormalities, 5 (vs 3) subgroups
3. Evaluation of depth of cytopenias
    Clinically and statistically relevant cutpoints used
4. Inclusion of differentiating features*
    Age, Performance Status, serum ferritin, LDH; β2-microglobulin
5. Prognostic model with 5 (vs 4) risk categories
    Improved predictive power
  • * For survival.

  • Provisional.